Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung - A Southwest Oncology Group study

Stephen K. Williamson; John J. Crowley; Robert Livingston; Alexander Hantel; James H. Doroshow

doi:10.1007/BF01275476

Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung - A Southwest Oncology Group study

Stephen K. Williamson
, John J. Crowley
, Robert Livingston
, Alexander Hantel
, James H. Doroshow

Cancer Center

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Piroxantrone demonstrated no activity in 17 eligible patients. Toxicity was acceptable and dose escalations were performed. With only 35% (6/17) of patients experiencing grade 2 or greater granulocytopenia the study might be criticized for utilizing a less than optimal dose of piroxantrone. Based on this trial, piroxantrone is not felt to have significant antitumor activity against advanced non-small cell carcinoma of the lung.

Original language	English (US)
Pages (from-to)	29-30
Number of pages	2
Journal	Investigational New Drugs
Volume	10
Issue number	1
DOIs	https://doi.org/10.1007/BF01275476
State	Published - Mar 1992

Keywords

lung cancer
non-small cell
phase II
piroxantrone

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF01275476

Cite this

@article{783caadff75241c29bc50d0c9b83602e,

title = "Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung - A Southwest Oncology Group study",

abstract = "Piroxantrone demonstrated no activity in 17 eligible patients. Toxicity was acceptable and dose escalations were performed. With only 35\% (6/17) of patients experiencing grade 2 or greater granulocytopenia the study might be criticized for utilizing a less than optimal dose of piroxantrone. Based on this trial, piroxantrone is not felt to have significant antitumor activity against advanced non-small cell carcinoma of the lung.",

keywords = "lung cancer, non-small cell, phase II, piroxantrone",

author = "Williamson, \{Stephen K.\} and Crowley, \{John J.\} and Robert Livingston and Alexander Hantel and Doroshow, \{James H.\}",

year = "1992",

month = mar,

doi = "10.1007/BF01275476",

language = "English (US)",

volume = "10",

pages = "29--30",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung - A Southwest Oncology Group study

AU - Williamson, Stephen K.

AU - Crowley, John J.

AU - Livingston, Robert

AU - Hantel, Alexander

AU - Doroshow, James H.

PY - 1992/3

Y1 - 1992/3

N2 - Piroxantrone demonstrated no activity in 17 eligible patients. Toxicity was acceptable and dose escalations were performed. With only 35% (6/17) of patients experiencing grade 2 or greater granulocytopenia the study might be criticized for utilizing a less than optimal dose of piroxantrone. Based on this trial, piroxantrone is not felt to have significant antitumor activity against advanced non-small cell carcinoma of the lung.

AB - Piroxantrone demonstrated no activity in 17 eligible patients. Toxicity was acceptable and dose escalations were performed. With only 35% (6/17) of patients experiencing grade 2 or greater granulocytopenia the study might be criticized for utilizing a less than optimal dose of piroxantrone. Based on this trial, piroxantrone is not felt to have significant antitumor activity against advanced non-small cell carcinoma of the lung.

KW - lung cancer

KW - non-small cell

KW - phase II

KW - piroxantrone

UR - https://www.scopus.com/pages/publications/0026780420

UR - https://www.scopus.com/pages/publications/0026780420#tab=citedBy

U2 - 10.1007/BF01275476

DO - 10.1007/BF01275476

M3 - Article

C2 - 1318871

AN - SCOPUS:0026780420

SN - 0167-6997

VL - 10

SP - 29

EP - 30

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 1

ER -

Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung - A Southwest Oncology Group study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this